Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[ 125/131I]AM2233

Synapse

Volumn 60, Issue 2, 2006, Pages 93-101

  Dhawan, Jasbeer ^a   Deng, Hongfeng ^b   Gatley, S John ^b   Makriyannis, Alexandros ^b   Akinfeleye, Tolulope ^a   Bruneus, Magalie ^a   Dimaio, Alexis A ^a   Gifford, Andrew N ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Agonist affinity states; Cannabinoids; CB1 receptor; In vivo binding; Receptor occupancy

Indexed keywords

(2 IODOPHENYL)[1 (1 METHYLPIPERIDIN 2 YLMETHYL) 1H INDOL 3 YL]METHANONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AM 2233; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; INDOLE DERIVATIVE; IODINE 125; IODINE 131; RADIOLIGAND; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CATALEPSY; CEREBELLUM; CORPUS STRIATUM; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG UPTAKE; EVALUATION; GLOBUS PALLIDUS; HIPPOCAMPUS; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ANIMAL; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INDOLES; IODINE RADIOISOTOPES; MALE; MICE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; NEURONS; PIPERIDINES; PROTEIN CONFORMATION; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1;

EID: 33745047486     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20277     Document Type: Article

References (30)

1. Berding G, Muller-Vahl K, Schneider U, Gielow P, Fitschen J, Stuhrmann M, Harke H, Buchert R, Donnerstag F, Hofmann M, Knoop BO, Brooks DJ, Emrich HM, Knapp WH. 2004. [(123)I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB(1) receptors before and after δ(9)- tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 55:904-915.
2. Bowyer JF, Weiner N. 1987. Modulation of the Ca++-evoked release of [3H]dopamine from striatal synaptosomes by dopamine (D2) agonists and antagonists. J Pharmacol Exp Ther 241:27-33.
3. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. 1992. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126.
4. Cosenza M, Gifford AN, Gatley SJ, Pyatt B, Liu Q, Makriyannis A, Volkow ND. 2000. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38:477-482.
5. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A. 2002. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci 965:440-450.
6. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Grego JD, Kullnig RK, Daley GT. 1992. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35:124-135.
7. De Lean A, Stadel JM, Lefkowitz RJ. 1980. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108-7117.
8. Deng H, Gifford AN, Cui G, Li X, Fan P, Deschamps JR, Flippen-Anderson JL, Gatley SJ, Makriyannis A. 2005. Potent cannabinergic indole analogs as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J Med Chem 48:6386-6392.
9. Fernandez JR, Allison DB. 2004. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 5:430-435.
10. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A. 1997. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61:191-197.
11. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A. 1998. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 70:417-423.
12. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND. 1998. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483.
13. Gifford AN, Bruneus M, Gatley SJ, Volkow ND. 2000. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br J Pharmacol 131:645-650.
14. Gifford AN, Makriyannis A, Volkow ND, Gatley SJ. 2002. In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 121:65-72.
15. Glass M, Faull RL, Dragunow M. 1993. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56:523-527.
16. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK. 2003. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000-2009.
17. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
18. Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, Yamamura HI. 1997. AM630 antagonism of cannabinoid-stimulated [35S]GTP γ S binding in the mouse brain. Eur J Pharmacol 321:R1-R3.
19. Hwang DR, Narendran R, Laruelle M. 2005. Positron-labeled dopamine agonists for probing the high affinity states of dopamine subtype 2 receptors. Bioconjug Chem 16:27-31.
20. Jansen EM, Haycock DA, Ward SJ, Seybold VS. 1992. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 575:93-102.
21. Kenakin T. 1995. Agonist-receptor efficacy. I. Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192.
22. Mathews WB, Scheffel U, Finley P, Ravert HT, Frank RA, Rinaldi-Carmona M, Barth F, Dannals RF. 2000. Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl Med Biol 27:757-762.
23. Mathews WB, Scheffel U, Rauseo PA, Ravert HT, Frank RA, Ellames GJ, Herbert JM, Barth F, Rinaldi-Carmona M, Dannals RF. 2002. Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nucl Med Biol 29:671-677.
24. Melichar JK, Hume SP, Williams TM, Daglish MR, Taylor LG, Ahmad R, Malizia AL, Brooks DJ, Myles JS, Lingford-Hughes A, Nutt DJ. 2005. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 312:309-315.
25. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. 1995. AM630, a competitive cannabinoid receptor antagonist. Life Sci 56:1949-1955.
26. Pertwee RG. 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
27. Petitet F, Jeantaud B, Capet M, Doble A. 1997. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. Biochem Pharmacol 54:1267-1270.
28. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Fertara P, Soubrie P, Breliere J-C, Le Fur G. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
29. Thomas BF, Compton DR, Martin BR. 1990. Characterization of the lipophilicity of natural and synthetic analogs of δ9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 255:624-630.
30. Willis PG, Pavlova OA, Chefer SI, Vaupel DB, Mukhin AG, Horti AG. 2005. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J Med Chem 48:5813-5822.